EMBioSys
PrivateLast Round
Grant
Nov 25, 2025
Total Funding Raised
$1.59M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
EMBioSys operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Grant round in November 2025.
EMBioSys is a medical technology company that develops non-invasive, wearable garments using induced electric field (iEF) therapy to treat aggressive cancers like triple-negative breast cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EMBioSys Comparables
Compare EMBioSys with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novocure | 71% | |
| QV Bioelectronics | 61% | |
| INIA Biosciences | 57% |
For institutional investors. Book with your work email.
EMBioSys Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 25, 2025 | ||||
| Seed | Apr 30, 2025 | ||||
| Grant | May 9, 2024 |
For institutional investors. Book with your work email.
EMBioSys Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 25, 2025
Received $1.38M from National Cancer Institute and NIH RADx.
- Apr 30, 2025
Raised $3M in a seed funding round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 7, 2026
EMBioSys Inc. partners with OSUCCC - James researchers to develop a wearable investigational device that generates low-intensity electric fields for cancer treatment; the early-stage technology undergoes testing in an upcoming National Institutes of Health-sponsored human clinical trial.
For institutional investors. Book with your work email.
EMBioSys Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EMBioSys's valuation, stock price, and market status.
Is EMBioSys a public or private company?
EMBioSys is a private company.
What is the current stock price of EMBioSys?
EMBioSys is a private company, so its shares have no public market price. Caplight tracks EMBioSys's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EMBioSys worth (valuation)?
Valuation information for EMBioSys is not publicly available.
Can I buy EMBioSys stock?
EMBioSys shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EMBioSys's last funding round?
EMBioSys's most recent funding round was Grant on November 25, 2025.
Who are the main investors in EMBioSys?
Key investors in EMBioSys include National Cancer Institute.
Will EMBioSys IPO soon?
No public IPO plans have been announced for EMBioSys.
How can I track EMBioSys secondary market activity?
Caplight tracks bids, offers, and trades in EMBioSys's shares on secondary markets.